Avacta Therapeutics recently presented a poster we collaborated on at EORTC-NCI-AACR 2024 entitled, "Affimer® Drug Conjugates Targeting Fibroblast Activation Protein-α." The poster highlights AffDCs as an innovative therapeutic class designed to deliver potent warheads with remarkable precision. Using the pre|CISION® release mechanism, these #AffDCs are activated only within the tumor microenvironment through FAP-specific cleavage. This ensures that the toxic payloads are delivered directly to cancer cells, sparing healthy tissues and enhancing tumor penetration. The poster also details how the smaller Affimer® proteins enable effective tumor targeting and robust bystander effects, advancing the promise of targeted biotherapeutics in oncology. Access the poster here: https://lnkd.in/gQ25pYUu #CancerResearch #OncologyInnovation #Biotherapeutics #CDMO #CRO #TargetedTherapy
Abzena’s Post
More Relevant Posts
-
At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, independent investigators presented preclinical data demonstrating the therapeutic potential of Cyclacel Pharmaceuticals, Inc. fadraciclib in colorectal cancer models. Fadraciclib significantly inhibited tumor growth, triggered apoptosis, and induced anaphase catastrophe in patient-derived organoids (PDOs) and xenografts (PDX). These findings support fadraciclib's potential as a novel treatment in multiple tumor types by targeting key molecular features of cancer. Learn more: https://bit.ly/3YliEaC #CancerResearch #Biotech #Innovation
-
-
Marc-Henry PITTY, MD, CEO of Oregon Therapeutics, "To date, our first-in-class #metabolicinhibitor, XCE853, has exhibited robust preclinical efficacy in both in vitro and in vivo models across multiple #cancer types. Lantern’s (NASDAQ: LTRN) #RADR®AI platform will leverage the in vitro and in vivo data to potentially advance XCE853 development in a highly targeted manner and will help inform disease indications and #biomarker signatures that can aid in the design of future #clinicaltrials and in the pursuit of combination therapies with other approved cancer drugs. Our team is looking forward to efficiently selecting among the landscape of ideal development options and efficiently de-risking future clinical development decisions." https://lnkd.in/g8XPQSsa #biotech #france #texas #oncology #artificialIntelligence
-
-
Today at #EANM24, we are presenting additional positive preclinical data supporting our DLL3-targeting #RadioDARPin Therapeutic (RDT) candidate MP0712, which is in co-development with Orano Med for patients with small cell lung cancer. Some highlights include: 🔹 Dose-dependent efficacy observed with favorable safety profile 🔹 Attractive tumor to kidney ratios shown in biodistribution studies 🔹 Picomolar affinity and high specificity for DLL3 seen strongly support anticipated precision of alpha radiation delivery 🔹 Molecular Partners and Orano Med are preparing for clinical entry in 2025 Stop by our oral presentation between 8-9:30 AM CET and learn more here: https://lnkd.in/eZm5F7Qn #radiopharmaceutical #oncology #cancerresearch
-
-
Marc-Henry PITTY, MD, CEO of Oregon Therapeutics, "To date, our first-in-class #metabolicinhibitor, XCE853, has exhibited robust preclinical efficacy in both in vitro and in vivo models across multiple #cancer types. Lantern’s (NASDAQ: LTRN) #RADR®AI platform will leverage the in vitro and in vivo data to potentially advance XCE853 development in a highly targeted manner and will help inform disease indications and #biomarker signatures that can aid in the design of future #clinicaltrials and in the pursuit of combination therapies with other approved cancer drugs. Our team is looking forward to efficiently selecting among the landscape of ideal development options and efficiently de-risking future clinical development decisions." https://lnkd.in/gabi_27S #biotech #france #texas #oncology #artificialIntelligence
-
-
How will #precisiononcology evolve in the upcoming year? Laksh Aithani, CEO of CHARM Therapeutics, shares his insights on the future of oncology in Scrip Asks' latest feature, "What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances." Laksh predicts significant advancements in precision oncology in 2024, particularly in the development of PRMT5 inhibitors for MTAP-deleted cancers, as well as the introduction of state-of-the-art ROS1 and ALK inhibitors in lung cancer treatments. Discover more about the predictions made by #biopharma leaders regarding the impact of #AI and innovative drug development strategies for 2024: https://lnkd.in/eNRMWRb8 #drugdevelopment #healthcareinnovation #CHARMTherapeutics
-
-
Early research on #cancer drugs that use SHINE Technologies' Illumira product found they could extend patients’ lifespans and more effectively treat #kidney and #prostate cancer, the Janesville company announced. The business and #WARF Therapeutics, the drug discovery program of the Wisconsin Alumni Research Foundation (WARF), recently released findings from research conducted at University of Wisconsin-Madison’s Advanced Radiotheranostics Lab. It focused on two treatments: #WT7695 and #ART101. Both include SHINE’s non-carrier added lutetium-177 chloride, called Illumira. The #radioactive isotope #Lu177 can kill cancer cells with a strong dose of #radiation guided by “cancer-seeking radiopharmaceutical agents,” while sparing healthy tissues. SHINE CEO and founder Greg Piefer says the research fundings offer “further validation that #Ilumira is more effective than the standard of care” for treating #cancer. 🔎 Read more at https://lnkd.in/gBG7tghG
-
-
Adcendo ApS, aiming to develop breakthrough Antibody Drug Conjugates (ADC) to treat underserved cancers, is one of the seven innovative companies listed in the Clarivate Companies to Watch report this year. The first-in-class (FIC) lead program targets the uPARAP receptor, which is overexpressed by several mesenchymal cancers, including soft tissue sarcoma (STS), bone sarcoma, gastrointestinal stromal tumors (GIST) and mesothelioma. Why is Adcendo ApS a company to watch? Download the report to discover innovations transforming drug discovery and development, revolutionizing cancer treatment, and capturing big pharma interest, here: https://lnkd.in/g_G6kvm4 #oncology #cancertreatement #biotech #pharma #companiestowatch
-
-
Great to see our CEO, Michael Pehl, highlighted by Clarivate following the publication of its 'Companies to Watch: Antibody Drug Conjugates' report! https://lnkd.in/dbTeNsct Learn more about Adcendo and our development of first-in-class #ADCs for the treatment of #cancer with a high unmet medical need in the report here: https://lnkd.in/eWhSzAWz #biotech #oncology #lifesciences
Adcendo ApS, aiming to develop breakthrough Antibody Drug Conjugates (ADC) to treat underserved cancers, is one of the seven innovative companies listed in the Clarivate Companies to Watch report this year. The first-in-class (FIC) lead program targets the uPARAP receptor, which is overexpressed by several mesenchymal cancers, including soft tissue sarcoma (STS), bone sarcoma, gastrointestinal stromal tumors (GIST) and mesothelioma. Why is Adcendo ApS a company to watch? Download the report to discover innovations transforming drug discovery and development, revolutionizing cancer treatment, and capturing big pharma interest, here: https://lnkd.in/g_G6kvm4 #oncology #cancertreatement #biotech #pharma #companiestowatch
-
-
What’s New for RNAi in 2025? The 6th RNAi-Based Therapeutics Summit is back with a fresh lineup of expert speakers within the RNAi space, including Armatus Bio, Inc., Benitec Biopharma Inc., Novartis, PepGen, and more. They will help refresh your understanding and explore the latest innovations in delivery technologies designed for precise and targeted therapeutic applications. Explore the official agenda here: https://ter.li/xmgwc2 But that's not all. The 2025 agenda will take a closer look at exciting new data on extra-hepatic targets, including preeclampsia, breast cancer, and fibrodysplasia ossificans progressive. Stay ahead of the curve and download the official summit brochure here: https://ter.li/v4wie2 #RNAi #RNAiTherapeutics #RNAiMedicines #Therapeutics #Networking #RNAiConference
-
-
What’s New for RNAi in 2025? The 6th RNAi-Based Therapeutics Summit is back with a fresh lineup of expert speakers within the RNAi space, including Armatus Bio, Inc., Benitec Biopharma Inc., Novartis, PepGen, and more. They will help refresh your understanding and explore the latest innovations in delivery technologies designed for precise and targeted therapeutic applications. Explore the official agenda here: https://ter.li/xmgwc2 But that's not all. The 2025 agenda will take a closer look at exciting new data on extra-hepatic targets, including preeclampsia, breast cancer, and fibrodysplasia ossificans progressive. Stay ahead of the curve and download the official summit brochure here: https://ter.li/v4wie2 #RNAi #RNAiTherapeutics #RNAiMedicines #Therapeutics #Networking #RNAiConference
-
